Lux Bioscience Brings In $50 Million To Take Luveniq To The Finish Line Alone
This article was originally published in The Pink Sheet Daily
Executive Summary
The ophthalmology specialist's inside round could take it through to launch of its lead product--or act as leverage in deal negotiations.